Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
- First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized
- REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile in Solid tumors and Lymphoma
- >100,000 patients in the US and EU5 initially addressable
- 第一个通过端到端使用操作系统来识别新靶标和新化学物质而得出的程序，该项目从靶标ID转移到IND，可以在不到18个月的时间内合成约200种化合物的研究
- REC-1245 是一种强效的选择性 RBM39 降解剂，在实体瘤和淋巴瘤中可能处于同类首创
- 美国和欧盟五国有超过 100,000 名患者最初可以接诊
SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.
盐湖城，2024年12月3日（GLOBE NEWSWIRE）——Recursion（纳斯达克股票代码：RXRX）是一家领先的临床阶段TechBio公司，致力于从根本上改善生活的生物学。该公司今天宣布，在用于治疗富含生物标志物的实体瘤和淋巴瘤的新化学实体 REC-1245 的1/2期临床试验中，第一位患者已经服药。
Recursion identified the novel regulatory role of RBM39 on CDK12 function using its AI-powered maps of biology. Recursion believes the modulation of RBM39 may be associated with a therapeutic effect in certain biomarker-enriched solid tumors and lymphoma. Preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.
递归使用其人工智能驱动的生物学地图确定了 RBM39 对 CDK12 功能的新调节作用。Recursion 认为，RBM39 的调节可能与某些富含生物标志物的实体瘤和淋巴瘤的治疗效果有关。临床前数据支持，RBM39 降解会诱发剪接缺陷，从而降低对 DNA 损伤响应 (DDR) 网络和细胞周期检查点的调节。
